EyeGate Pharmaceuticals (NASDAQ:EYEG) has received an additional development milestone from a subsidiary of Valeant Pharmaceuticals International (NYSE, TSX:VRX). EyeGate previously granted Valeant exclusive, worldwide...

IntelGenx (OTCQX:IGXT; TSX-V:IGX) has entered into a licensing, development and supply agreement with closely-held Chemo Group, granting Chemo the exclusive license to commercialize two generic products for the U.S...

Episodic cluster headache patients using electroCore’s gammaCore non-invasive vagus nerve stimulation device (nVNS) had a significant and clinically meaningful benefit within 15 minutes of an attack treatment, compared...

Dipexium Pharmaceuticals (NASDAQ:DPRX) said that the European Patent Office has issued a new Locilex patent in the EU. The patent claims are directed to a novel formulation of Locilex, a topical antimicrobial peptide...

Tonix Pharmaceuticals Holding (NASDAQ:TNXP) said its Phase 3 AFFIRM study, designed to evaluate the safety and efficacy of TNX-102 SL in patients with fibromyalgia, did not achieve statistical significance in the...

Closely-held ASLAN Pharmaceuticals has licensed a novel immuno-oncology antibody, targeting RON (Recepteur d’Origine Nantais), from Singapore’s Agency for Science, Technology and Research (A*STAR). RON is a receptor...

Mesoblast (NASDAQ:MESO; ASX:MSB) appointed William Burns, a director, as vice chairman. In this role, Mr. Burns, a former CEO of Roche Pharmaceuticals from 2001 to 2009, will focus his considerable pharmaceutical...

Valeant Canada, a subsidiary of Valeant Pharmaceuticals International (NYSE, TSX: VRX), will commercialize Orexigen Therapeutics’ (NASDAQ:OREX) Contrave (naltrexone HCl / bupropion HCl extended release) in Canada. Under...

ARIAD Pharmaceuticals (NASDAQ:ARIA) has completed a rolling NDA submission to the FDA for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib. ARIAD is seeking U.S. marketing approval of...

The FDA has granted orphan-drug status to Regenicin’s (OTC:RGIN) NovaDerm cultured skin substitute. In a statement, the company said it believes NovaDerm to be the only autologous cultured skin substitute prepared from...

IntelGenx (OTCQX:IGXT; TSX-V:IGX) has completed a pilot clinical study for montelukast VersaFilm that demonstrated a significantly improved pharmacokinetic profile against the reference product. Montelukast is a unique...

StemCells (NASDAQ:STEM) and closely-held Microbot Medical of Israel have entered into a definitive merger agreement, with plans to pursue the development of robotics-based medical devices for the treatment of...

Leerink reiterated its “outperform” rating on Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) after the reported top-line results with voclosporin in a Phase 2b clinical study in patients with active lupus nephritis...

IntelGenx (OTCQX:IGXT; TSX-V:IGX) has sold its royalty on future sales of Forfivo XL to SWK Holdings for $6-million. Forfivo XL (bupropion extended release) is the first 450-milligram bupropion hydrogen chloride tablet...

Galectin Therapeutics (NASDAQ:GALT) has completed patient recruitment in its Phase 2 clinical trial with GR-MD-02 in patients with non-alcoholic steatohepatitis (NASH) with cirrhosis, the NASH-CX trial. The company...

Cellect Biotechnology (NASDAQ:APOP; TASE:CLBD) priced an initial public offering in the U.S. of 1,292,308 American Depository Shares (ADSs) and warrants to purchase up to 969,231 ADSs. Each ADS, representing 20 ordinary...

Oramed Pharmaceuticals (NASDAQ:ORMP) has received a milestone payment of $4-million from Hefei Tianhui Incubator of Technologies (HTIT) of China. The milestone is part of a license and investment agreement between...

New York’s WPIX-TV has produced a segment about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine as a new treatment in the battle against heroin and prescription painkiller addiction. The FDA...

ProMIS Neurosciences (TSX:PMN) released results in two presentations of its recent therapeutic developments at the Alzheimer’s Association International Conference in Toronto. “Our results presented at the AAIC meeting...

Oramed Pharmaceuticals (NASDAQ:ORMP) reported additional data from the recently concluded Phase 2b trial of its oral insulin capsule ORMD-0801 in adults with Type 2 diabetes. The data indicate a statistically...